قالب وردپرس درنا توس
Home / Business / 2 lagging stocks that can still win the COVID vaccine race

2 lagging stocks that can still win the COVID vaccine race



Pfizer (New York Stock Exchange: PFE), And its partners Biological Technology (Nasdaq stock code: BNTX)with modern (Nasdaq stock code: MRNA) There is no doubt that the clear leader in the COVID-19 market is now. Some Americans are already receiving the company’s vaccine, and many more are waiting for the vaccine.

But are there other stocks that can still win the COVID-19 vaccine contest?at this Motley Fool Live In a video recorded on December 18, 2020, Corinne Cardina, Director of the Bureau of Health Care and Marijuana, and April Fool’s Day writer Keith Speights discuss two stocks, they may Like the tortoise in Aesop̵

7;s famous fable about the tortoise and the hare.

Corinne Cardina: Let’s talk about some Slido issues. James wants to know which companies are currently developing vaccines that meet the doctor’s recommendations. Keith, can you talk about one or two of the tortoise companies that might actually get started and really help the pandemic instead of being named Moderna, Pfizer and BioNTech?

Keith Speights: of course. Well, for example, Dr. Galin mentioned a single-dose vaccine.Well, the leader in this area is Johnson (New York Stock Exchange: JNJ).

Johnson & Johnson is developing a single-dose vaccine. Johnson & Johnson said that they will announce the efficacy results in January, hoping to apply for emergency use authorization, and hope to receive it in February. Therefore, this is a vaccine that is expected to be marketed soon, and it is a single-dose vaccine. As I mentioned before, I am very interested in understanding the power of Johnson & Johnson. I really hope it will at least stand out in our collaboration with Pfizer and Moderna. Therefore, this is a very important consideration.

There is another company called the dark horse in the competition, Arcturus Therapeutics (Nasdaq stock code: ARCT), ARCT is the code. Arcturus also has a single-dose vaccine. The difference is that it is also a messenger RNA vaccine, just like Pfizer and Moderna’s vaccines. We have seen the safety and efficacy profiles of two different mRNA vaccines, and they both look very good, so I think this is a good sign for the Arcturus vaccine also has good safety and efficacy.

Again, it is a single dose, and they are working on a freeze-dried version of it. They plan to enter a later stage study, and hope it will be available soon. This will help them solve some of their cold storage needs. In this way, Dr. Green mentioned several boxes. Therefore, if all goes well, the two companies are undergoing clinical testing and I think their vaccines are very promising.




Source link